Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.nejm.org" to "https://www.nejm.org") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref>[https://www.sanofioncology.com/pipeline/semuloparin.aspx Semuloparin (AVE5026) manufacturer's website]</ref><ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [ | + | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref>[https://www.sanofioncology.com/pipeline/semuloparin.aspx Semuloparin (AVE5026) manufacturer's website]</ref><ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [https://www.nejm.org/doi/full/10.1056/NEJMoa1108898 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22335737 PubMed]</ref> |
Route: SC | Route: SC | ||
Revision as of 00:29, 7 December 2018
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]
Route: SC
Extravasation: n/a
Patient drug information
No information available.
References
- ↑ Semuloparin (AVE5026) manufacturer's website
- ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed